Quantcast

Latest epilepsy Stories

2014-10-30 08:36:07

HOUSTON, Oct. 30, 2014 /PRNewswire/ -- Texas Children's Hospital is a site for the first worldwide clinical trial testing the safety and efficacy of Epidiolex® in children and adolescents with Dravet syndrome, a catastrophic form of intractable epilepsy that begins in early infancy. The trial will have two parts, with the first part determining ideal dosage for the drug, and the second part evaluating the drug's safety and efficacy. Beginning this month, the trial will enroll 30...

2014-10-24 08:25:17

Winner to be Featured in Third Book of Epilepsy Education Comic Book Series WOODCLIFF LAKE, N.J., Oct. 24, 2014 /PRNewswire/ -- Eisai Inc., a leader in the epilepsy community, announces the launch of the "Search for the Next Medikidz Star," a consumer contest to identify a child living with epilepsy who will star in the next installment of the "Medikidz Explain Epilepsy" comic book series. To view the multimedia assets associated with this release, please click:...

2014-10-23 12:29:35

Findings Presented at 43rd Annual Meeting of the Child Neurology Society MAPLE GROVE, Minn., Oct. 23, 2014 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), today announced the presentation of results from an in vitro study in which Qudexy(TM) XR (topiramate) extended-release capsules were opened and the capsule contents (extended-release beads) were passed through enteral feeding tubes of various sizes, utilizing different diluents. The data were presented at the 43(rd) Annual...

2014-10-22 08:30:29

Seattle and Spokane Host Conferences SEATTLE, Oct. 22, 2014 /PRNewswire-USNewswire/ -- Dr. Jeffrey Bucchalter, Director of the Comprehensive Children's Epilepsy Center at Alberta Children's Hospital. Dr. Bucchalter will speak on Sudden Unexpected Death in Epilepsy (SUDEP) - A Conversation Based on Risk and Empathy. SUDEP is the leading cause of premature death among people with epilepsy, and an epilepsy topic gaining more attention in research and patient-provider relationships....

2014-10-21 08:33:00

Subcutaneous Trigeminal Nerve Stimulation (sTNS) for the Treatment of Neuropsychiatric Disorders LOS ANGELES, Oct. 21, 2014 /PRNewswire/ - NeuroSigma(®), Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS system for the treatment of neurological and neuropsychiatric disorders, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No....

2014-10-20 08:32:26

WOODCLIFF LAKE, N.J., Oct. 20, 2014 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures, a severe form of seizures, in patients 12 years and older. FYCOMPA((TM)) (perampanel) CIII, which was approved by the FDA in October 2012 and became...

2014-10-19 23:00:34

RnRMarketResearch.com adds “Partial Seizure – Pipeline Review, H2 2014” to its store. The report provides an overview of the Tinnitus’s therapeutic pipeline. Dallas, Texas (PRWEB) October 20, 2014 This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest...

2014-10-16 23:03:50

The AKC Canine Health Foundation (CHF) announces the funding of grants for canine epilepsy and hypothyroidism. Raleigh, NC (PRWEB) October 16, 2014 The AKC Canine Health Foundation (CHF) today announces the funding of two grants for canine epilepsy and one grant for canine hypothyroidism. These grants, totaling over $268,000 in funding will ultimately equip veterinarians with more effective treatments and researchers with a better understanding of the underlying mechanisms that cause...

2014-10-15 20:22:40

SCHOFIELD, Wis., Oct. 15, 2014 /PRNewswire/ -- PuraMed BioScience(®), Inc., (OTCPink: PMBSD), a researcher, developer, and marketer of over-the-counter medicinal and healthcare products, announced that Ludlow Research has issued a research opinion of the Company based on the pending launch of its rebranded migraine product, MigraPure, the development of a hemp-based epilepsy symptom treatment, and the Company's current valuation. The Company recently announced development of an...

2014-10-15 08:29:15

Phase 1 Clinical Trial - External Trigeminal Nerve Stimulation for Traumatic Brain Injury LOS ANGELES, Oct. 15, 2014 /PRNewswire/ -- NeuroSigma(®), Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Veterans Affairs (VA) for a...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.